Parisi R., Iskandar I.Y.K., Kontopantelis E., Augustin M., Griffiths C.E.M., Ashcroft D.M. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. https://doi.org/10.1136/bmj.m1590..
DOI: 10.1136/bmj.m1590
Jiaravuthisan M.M., Sasseville D., Vender R.B., Murphy F., Muhn C.Y. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1–27. https://doi.org/10.1016/j.jaad.2005.07.073..
DOI: 10.1016/j.jaad.2005.07.073
Wolska H. Nail psoriasis. Przegl Dermatol. 2010;97:243–253.
de Jong E.M., Seegers B.A., Gulinck M.K., Boezeman J.B., van de Kerkhof P.C. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996;193(4):300–303. https://doi.org/10.1159/000246274..
DOI: 10.1159/000246274
Ortonne J.P., Baran R., Corvest M., Schmitt C., Voisard J.J., Taieb C. Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol. 2010;24(1):22–27. https://doi.org/10.1111/j.1468-3083.2009.03344.x..
DOI: 10.1111/j.1468-3083.2009.03344.x
Rapp S.R., Feldman S.R., Exum M.L., Fleischer A.B. Jr., Reboussin D.M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401–407. https://doi.org/10.1016/s0190-9622(99)70112-x..
DOI: 10.1016/s0190-9622(99)70112-x
Bardazzi F., Lambertini M., Chessa M.A., Magnano M., Patrizi A., Piraccini B.M. Nail involvement as a negative prognostic factor in biological therapy for psoriasis: a retrospective study. J Eur Acad Dermatol Venereol. 2017;31(5):843–846. https://doi.org/10.1111/jdv.13979..
DOI: 10.1111/jdv.13979
Ventura A., Mazzeo M., Gaziano R., Galluzzo M., Bianchi L., Campione E. New insight into the pathogenesis of nail psoriasis and overview of treatment strategies. Drug Des Devel Ther. 2017;11:2527–2535. https://doi.org/10.2147/dddt.s136986..
DOI: 10.2147/dddt.s136986
Crowley J.J., Weinberg J.M., Wu J.J., Robertson A.D., Van Voorhees A.S. Treatment of nail psoriasis: best practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol. 2015;151(1):87–94. https://doi.org/10.1001/jamadermatol.2014.2983..
DOI: 10.1001/jamadermatol.2014.2983
Salomon J., Szepietowski J.C., Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg. 2003;7(4):317–321. https://doi.org/10.1007/s10227-002-0143-0..
DOI: 10.1007/s10227-002-0143-0
Pasch M.C. Nail Psoriasis: A Review of Treatment Options. Drugs. 2016;76(6):675–705. https://doi.org/10.1007/s40265-016-0564-5..
DOI: 10.1007/s40265-016-0564-5
Klaassen K.M., van de Kerkhof P.C., Pasch M.C. Nail psoriasis: a questionnaire-based survey. Br J Dermatol. 2013;169(2):314–319. https://doi.org/10.1111/bjd.12354..
DOI: 10.1111/bjd.12354
Augustin M., Reich K., Blome C., Schäfer I., Laass A., Radtke M.A. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol. 2010;163(3):580–585.
Потекаев Н.Н., Жукова О.В., Артемьева С.И. Успешное применение препарата нетакимаб при лечении псориаза, сопровождающегося явлениями псориатической ониходистрофии. Медицинский совет. 2020;(12):64–70. https://doi.org/10.21518/2079-701X-2020-12-64-70..
DOI: 10.21518/2079-701X-2020-12-64-70
Rouzaud M., Sevrain M., Villani A.P., Barnetche T., Paul C., Richard M.A. et al. Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. J Eur Acad Dermatol Venereol. 2014;28(5 Suppl.):17–26. https://doi.org/10.1111/jdv.12562..
DOI: 10.1111/jdv.12562
Langenbruch A., Radtke M.A., Krensel M., Jacobi A., Reich K., Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171(5):1123–1128. https://doi.org/10.1111/bjd.13272..
DOI: 10.1111/bjd.13272
Raposo I., Torres T. Nail psoriasis as a predictor of the development of psoriatic arthritis. Actas Dermosifiliogr. 2015;106(6):452–457. https://doi.org/10.1016/j.ad.2015.02.005..
DOI: 10.1016/j.ad.2015.02.005
Haneke E. Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management. Psoriasis (Auckl). 2017;7:51–63. https://doi.org/10.2147/ptt.s126281..
DOI: 10.2147/ptt.s126281
Tan A.L., Benjamin M., Toumi H., Grainger A.J., Tanner S.F., Emery P., McGonagle D. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis – a high-resolution MRI and histological study. Rheumatology (Oxford). 2007;46(2):253–256. https://doi.org/10.1093/rheumatology/kel214..
DOI: 10.1093/rheumatology/kel214
McGonagle D., Palmou Fontana N., Tan A.L., Benjamin M. Nailing down the genetic and immunological basis for psoriatic disease. Dermatology. 2010;221(1 Suppl.):15–22. https://doi.org/10.1159/000316171..
DOI: 10.1159/000316171
Aydin S.Z., Castillo-Gallego C., Ash Z.R., Marzo-Ortega H., Emery P., Wakefield R.J. et al. Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy. Dermatology. 2012;225(3):231–235. https://doi.org/10.1159/000343607..
DOI: 10.1159/000343607
Sandre M.K., Rohekar S., Guenther L. Psoriatic Nail Changes Are Associated With Clinical Outcomes in Psoriatic Arthritis. J Cutan Med Surg. 2015;19(4):367–376. https://doi.org/10.1177/1203475415573663..
DOI: 10.1177/1203475415573663
Schons K.R., Beber A.A., Beck M.O., Monticielo O.A. Nail involvement in adult patients with plaque-type psoriasis: prevalence and clinical features. An Bras Dermatol. 2015;90(3):314–319. https://doi.org/10.1590/abd1806-4841.20153736..
DOI: 10.1590/abd1806-4841.20153736
de Berker D. Management of nail psoriasis. Clin Exp Dermatol. 2000;25(5):357–362. https://doi.org/10.1046/j.1365-2230.2000.00663.x..
DOI: 10.1046/j.1365-2230.2000.00663.x
Al-Mutairi N., Noor T., Al-Haddad A. Single Blinded Left-to-Right Comparison Study of Excimer Laser Versus Pulsed Dye Laser for the Treatment of Nail Psoriasis. Dermatol Ther (Heidelb). 2014;4(2):197–205. https://doi.org/10.1007/s13555-014-0057-y..
DOI: 10.1007/s13555-014-0057-y
Boontaveeyuwat E., Silpa-Archa N., Danchaivijitr N., Wongpraparut C. A randomized comparison of efficacy and safety of intralesional triamcinolone injection and clobetasol propionate ointment for psoriatic nails. J Dermatolog Treat. 2019;30(2):117–122. https://doi.org/10.1080/09546634.2018.1476647..
DOI: 10.1080/09546634.2018.1476647
Rigopoulos D., Gregoriou S., Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1[%] vs. clobetasol propionate 0.05[%] cream: a double-blind study. Acta Derm Venereol. 2007;87(2):167–168. https://doi.org/10.2340/00015555-0195..
DOI: 10.2340/00015555-0195
Thomas L., Azad J., Takwale A. Management of nail psoriasis. Clin Exp Dermatol. 2021;46(1):3–8. https://doi.org/10.1111/ced.14314..
DOI: 10.1111/ced.14314
Zhang X., Xie B., He Y. Efficacy of Systemic Treatments of Nail Psoriasis: A Systemic Literature Review and Meta-Analysis. Front Med (Lausanne). 2021;8:620562. https://doi.org/10.3389/fmed.2021.620562..
DOI: 10.3389/fmed.2021.620562
Reich K., Sullivan J., Arenberger P., Mrowietz U., Jazayeri S., Augustin M. et al. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial. Br J Dermatol. 2019;181(5):954–966. https://doi.org/10.1111/bjd.17351..
DOI: 10.1111/bjd.17351
Nash P., Mease P.J., Kirkham B., Balsa A., Singhal A., Quebe-Fehling E. et al. FRI0457 Secukinumab provides significant and sustained improvement in nail psoriasis and signs and symptoms of psoriatic arthritis in patients with nail phenotype: 52-week results from the phase iii future 5 study. Ann Rheum Dis. 2019;78:921–922. https//doi.org/10.1136/annrheumdis-2019-eular.2531.
Gottlieb A.B., Mease P., McInnes I.B., Kirkham B., Kavanaugh A., Rahman P. et al. Secukinumab, a human anti-interleukin-17a monoclonal antibody, significantly reduces psoriasis burden in patients with psoriatic arthritis: results from a phase 3 randomized controlled trial. Arthritis Rheumatol. 2014;66:S233. Available at: https://acrabstracts.org/abstract/secukinumaba-human-anti-interleukin-17a-monoclonal-antibody-significantly-reducespsoriasis-burden-in-patients-with-psoriatic-arthritis-results-from-a-phase-3-randomized-controlled-trial.https://acrabstracts.org/abstract/secukinumaba-human-anti-interleukin-17a-monoclonal-antibody-significantly-reducespsoriasis-burden-in-patients-with-psoriatic-arthritis-results-from-a-phase-3-randomized-controlled-trial
Gottlieb A.B., Mease P., McInnes I.B., Kirkham B., Kavanaugh A., Rahman P. et al. Secukinumab, a human anti-interleukin-17a monoclonal antibody, significantly reduces psoriasis burden in patients with psoriatic arthritis: results from a phase 3 randomized controlled trial. Arthritis Rheumatol. 2014;66:S233. Available at: https://acrabstracts.org/abstract/secukinumaba-human-anti-interleukin-17a-monoclonal-antibody-significantly-reducespsoriasis-burden-in-patients-with-psoriatic-arthritis-results-from-a-phase-3-randomized-controlled-trial.https://acrabstracts.org/abstract/secukinumaba-human-anti-interleukin-17a-monoclonal-antibody-significantly-reducespsoriasis-burden-in-patients-with-psoriatic-arthritis-results-from-a-phase-3-randomized-controlled-trial
Leonardi C., Matheson R., Zachariae C., Cameron G., Li L., Edson-Heredia E. et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–1199. https://doi.org/10.1056/nejmoa1109997..
DOI: 10.1056/nejmoa1109997
Mease P.J., van der Heijde D., Ritchlin C.T., Okada M., Cuchacovich R.S., Shuler C.L. et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79–87. https://doi.org/10.1136/annrheumdis-2016-209709..
DOI: 10.1136/annrheumdis-2016-209709
Wasel N., Thaçi D., French L.E., Conrad C., Dutronc Y., Gallo G. et al. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). Dermatol Ther (Heidelb). 2020;10(4):663–670. https://doi.org/10.1007/s13555-020-00383-x..
DOI: 10.1007/s13555-020-00383-x
Leonardi C., Reich K., Foley P., Torii H., Gerdes S., Guenther L. et al. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatol Ther (Heidelb). 2020;10(3):431–447. https://doi.org/10.1007/s13555-020-00367-x..
DOI: 10.1007/s13555-020-00367-x
van de Kerkhof P., Guenther L., Gottlieb A.B., Sebastian M., Wu J.J., Foley P. et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31(3):477–482. https://doi.org/10.1111/jdv.14033..
DOI: 10.1111/jdv.14033
Mease P.J., Smolen J.S., Behrens F., Nash P., Liu Leage S., Li L. et al. A headto-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123–131. https://doi.org/10.1136/annrheumdis-2019-215386..
DOI: 10.1136/annrheumdis-2019-215386
Кубанов А.А., Бакулев А.Л., Самцов А.В., Хайрутдинов В.Р., Соколовский Е.В., Кохан М.М. и др. Нетакимаб – новый ингибитор ИЛ-17а: результаты 12 недель клинического исследования III фазы BCD-085-7/PLANETA у пациентов со среднетяжелым и тяжелым вульгарным псориазом. Вестник дерматологии и венерологии. 2019;(2):15–28. https://doi.org/10.25208/0042-4609-2019-95-2-15-28..
DOI: 10.25208/0042-4609-2019-95-2-15-28
Пуч Л., Бакулев А.Л., Кохан М.М., Самцов А.В., Хайрутдинов В.Р., Морозова М.А. и др. Эффективность и безопасность нового моноклонального антитела к ИЛ-17 нетакимаба у пациентов со среднетяжелым и тяжелым бляшечным псориазом. Результаты 54-недельного рандомизированного двойного слепого плацебо-контролируемого клинического исследования PLANETA. Вестник дерматологии и венерологии. 2021;(4):80–91. (In Russ.) https://doi.org/10.25208/vdv1251..
DOI: 10.25208/vdv1251
Круглова Л.С., Переверзина Н.О. Эффективность раннего назначения блокаторов интерлейкина-17 в терапии аксиальных поражений при псориатическом артрите. Фарматека. 2021;(14):22–26. https://doi.org/10.18565/pharmateca.2021.14.22-26..
DOI: 10.18565/pharmateca.2021.14.22-26
Коротаева Т.В., Мазуров В.И., Лила А.М., Гайдукова И.З., Бакулев А.Л., Самцов А.В. и др. Эффективность и безопасность нетакимаба у пациентов с псориатическим артритом: результаты клинического исследования III фазы PATERA. Научно-практическая ревматология. 2020;(5):480–488. https://doi.org/10.47360/1995-4484-2020-480-488..
DOI: 10.47360/1995-4484-2020-480-488